For context, participants in the STEP 1 clinical trial taking 2.4 mg of semaglutide lost an average of 14.9% of their body weight over 68 weeks
For many, this is transient
Activos liposomados
Patikorn, C., Saidoung, P., Pham, T
Along with the new oral version of the GLP-1 agonist that has made a strong commercial start since its launch in the US earlier this year, the high-dose injectable version is one of the assets Novo Nordisk is hoping will help staunch the loss in market share in obesity caused by the rapid growth of Wegovy's main rival, Eli Lilly's Zepbound/Mounjaro (tirzepatide), which outperformed the original 2.4 mg Wegovy formulation in head-to-head trials
081X(200001)21:1 3.0.CO;2-H Nave, R., Peled, R., & Lavie, P